Ovarian carcinoma is the most lethal gynaecological malignancy. Better understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes. MicroRNAs play important roles in cancer progression and have the potential for use as either therapeutic agents or targets. Studies in other cancers have suggested that miR-506 has anti-tumour activity, but its function has yet to be elucidated. We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.
Introduction
Ovarian carcinoma is the most lethal gynaecological malignancy in the USA. In 2013, an estimated 22 240 new cases were diagnosed and 14 030 women died of the disease [1] . Ovarian cancer is frequently referred to as the 'silent killer', as the majority of cases are diagnosed at an advanced stage [2, 3] . Improved understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes [4, 5] . Alteration of microRNA (miRNA) expression has been observed in ovarian cancer, suggesting that a dysfunction of miRNA may be associated with tumourigenesis and progression of this disease [6] [7] [8] .
A recent study showed that restoration of microRNA 506 (miR-506) in malignant transformed human bronchial epithelial cells led to a decrease in cell proliferation [9] . Streicher et al reported that the miR-506-514 cluster plays an oncogenic role in initiating melanocyte transformation and in promoting melanoma growth [10] . The role of miR-506 in ovarian tumourigenesis and tumour progression, and the molecular mechanisms by which miR-506 exerts its effects, remain largely unknown [9] [10] [11] . Recently, through integrated genomic analysis of miRNA regulatory networks from The Cancer Genome Atlas (TCGA) data, we showed that miR-506 augmented E-cadherin expression and prevented TGFβ-induced epithelial-mesenchymal transition (EMT) by targeting SNAI2 in ovarian cancer [12] .
Here we report that deregulation of miR-506 in ovarian cancer is important in the acquisition of an aggressive tumour phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and promote senescence. More importantly, we provide evidence that miR-506 directly targets both CDK4 and CDK6. MiR-506 also inhibited signalling in CDK4/6-FOXM1, the transcription factor network activated in more than 80% of high-grade serous ovarian cancer cases [13] . Collectively, our results provide an experimental basis for investigating miR-506 as a potential therapeutic for ovarian cancer.
Materials and methods

Cell lines, cell culture, reagents and miRNA transfection
Ovarian cancer cell lines HeyA8, SKOV3, OVCA432 and OVCA433 and cervical cancer HeLa cells were cultivated with RPMI1640 medium supplemented with 10% fetal bovine serum (FBS). The miRNA mimic of miR-506 and negative control (miR-ctrl) were obtained from Dharmacon (Chicago, IL, USA). The antisense miR-506 (anti-miR-506) locked nucleic acid (LNA) and negative control were obtained from EXIQON (Woburn, MA, USA). SiRNA for CDK4 (SASI_Hs01_00122488, 00122490) and CDK6 (SASI_Hs01_00048792, 00048790) were obtained from Sigma (St. Louis, MO, USA). Cells were seeded at 2 × 10 5 /well in six-well plates and allowed to attach for at least 16 h. MiR-506 mimic, anti-miR-506 LNA, and miR-ctrl were transfected using Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY, USA) at a final concentration of 20 nM. Total RNA and protein were collected 48 h after transfection.
Real-time RT-PCR analysis and microarray gene expression analysis
Total RNA was isolated using the miRvana miRNA isolation kit (Ambion, Grand Island, NY, USA). Reverse transcription was performed by using SuperScript II Reverse Transcriptase (Invitrogen), according to the manufacturer's protocol. TaqMan real-time polymerase chain reaction (PCR) assays for miR-506, CDK4 and CDK6 were obtained from Applied Biosciences (Grand Island, NY, USA). Cyclophilin and β-actin were used as normalization controls. Data were analysed by the -2ΔΔ CT method.
Microarray experiments were carried out using whole human genome oligoarrays with 44 k 60-mer probes (Agilent Technologies, Palo Alto, CA, USA), with 500 ng total RNA starting material, according to the manufacturer's protocol. Hybridized arrays were scanned with Agilent's dual laser-based scanner. Feature Extraction software v 8.0 (Agilent Technologies) was used to link a feature to a design file and to determine the relative fluorescence intensities of the two samples. The microarray data are publicly available at GEO (Accession No.GSE50850).
Cell cycle analysis
At 48 h after transfection, cells were harvested, washed with phosphate-buffered saline solution (PBS) and fixed in 70% ethanol at 4 ∘ C overnight. After fixation, cells were washed twice with PBS before resuspension in propidium iodide/RNase A solution (5 μg/ml propidium iodide and 100 mg/ml RNase A). Cells were incubated with propidium iodide at room temperature in the dark for 1 h. Stained cells were analysed by flow cytometry for light-scattering properties and for DNA content, using a FACScan flow cytometer (BD Biosciences, Mountain View, CA, USA), and G 0-1 , S and G 2 -M fractions were determined.
MTT assay
For cell viability assays, cells were transfected with miR-506 or miR-ctrl, using Lipofectamine RNAiMAX. At 24 h after transfection, cells were seeded in a 96-well plate at a density of 1 × 10 3 /well. After incubation for 24, 48, 72 or 96 h at 37 ∘ C in a humidified incubator, 20 μl MTT (5 mg/ml in PBS) was added to each well, and the cells were incubated for a further 4 h. After removal of the medium, 150 μl dimethyl sulphoxide was added to each well. The absorbance was recorded on a microplate reader at a wavelength of 540 nm.
BrdU assay
Cell proliferation was assessed using a fluorescein isothiocyanate (FITC)-bromodeoxyuridine (BrdU) flow kit (BD Pharmingen, San Diego, CA, USA). Briefly, 48 h after transfection, cells were treated with 10 μM BrdU for 1 h, harvested and stained with FITC-conjugated anti-BrdU antibody and 7AAD, according to the manufacturer's instructions.
Colony-formation assay
Cells were harvested 24 h after transfection with 20 nM miR-506 or miR-ctrl. Transfected cells were seeded in a fresh six-well plate (500 cells/well) and kept in culture undisturbed for 10-14 days, during which time the surviving cells spawned colonies of proliferating cells. Colony formation was analysed by staining the cells with 0.1% crystal violet. The rate of colony formation was calculated using the following equation: colony formation rate = (number of colonies/number of seeded cells) × 100%.
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analysed by FACS to determine proliferating or apoptotic fractions.
Western blot analysis
Primary antibody for β-actin was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). CDK4 and CDK6 antibodies were purchased from Cell Signaling Technology (Boston, MA, USA). CyclinD1 and cyclinD3 antibodies were obtained from Thermo Scientific (Waltham, MA, USA) and Sigma, respectively. Western blotting was performed by loading whole-cell lysate (30 μg) from each sample onto a 10% polyacrylamide gel for electrophoresis. The membrane was blocked in 5% non-fat milk in 1× Tris-buffered saline solution, pH 7.4, containing 0.05% Tween-20 and probed with primary antibodies at a concentration of 1:1000 (for β-actin, CDK4, CDK6, cyclinD3 and β-tubulin) or 1:200 (for cyclinD1). The secondary antibodies were used at a concentration of 1:10 000-1:20 000. The proteins were visualized using the SuperSignal West Pico or SuperSignal Femtochemiluminescent substrate from Pierce Chemical (Rockford, IL, USA).
Luciferase reporter assay
The 3 ′ -untranslated regions (3 ′ -UTRs) of CDK4 and CDK6, which contained the predicted binding sites of miR-506, were amplified separately from normal fetal genomic DNA by PCR, using the following specific primers: CDK4, forward GGCGAGCTCTGAGCAATG GAGTGGCTGCC, reverse GGCCTCGAGAAGACC ATTATTTCTTTGTTTTGTTTTTCCTG; CDK6-U1, forward GGCGAGCTCTCGCAGTCTCAGCTTATG, reverse GGCCTCGAGCCTTGAATGCTGTGGATTC; and CDK6-U2, forward GGCGAGCTCAACTGAAG-GCAGAAAGTGTTAG, reverse GGCCTCGAGCTG-TATGTGACAGTCTTCCTG.
The PCR products were cloned into the pmirGLO-control vector between the SacI and XhoI sites or the SacI and XbaI sites in the correct direction. The consensus miR-506 binding sites in the 3 ′ -UTRs of CDK4 and CDK6 were deleted by PCR, using a QuikChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The following primers were used: CDK4, forward CTACAGAGAT-TACTTTGCAATGACATTCCCCTC, reverse GAGGG GAATGTCATTGCAAAGTAATCTCTGTAG; CDK6, forward 1 GTGCTTATTTCTAGTGCTCACTCCTGCT CTC, reverse 1 GAGAGCAGGAGTGAGCACTAGAA ATAAGCAC; forward 2 CCTTTATATTTCATACCATC TCTAAGTGGTTTAGTGCTCAG, reverse 2 CTGAG CACTAAACCACTTAGAGATGGTATGAAATATAAA GG; forward 3 GTAGAAAAGCATTTTAGATAATT-TAGAAACTGTGCCAGGTG, reverse 3 CACCTGGC ACAGTTTCTAAATTATCTAAAATGCTTTTCTAC; and forward 4 GAACTGTCAGCTTGAGGCTTCCA-GAACG, reverse4 CGTTCTGGAAGCCTCAAGCT-GACAGTTC. All clones were verified by DNA sequencing.
For the luciferase reporter assay, subconfluent HeLa cells in 24-well plates were transfected with a triplicate repeat of pmirGLO reporter plasmid (0.5 μg) wild-type or mutant 3 ′ -UTR construct, miR-506 mimic or miR-ctrl (50 nM) and Lipofectamine 2000 (2 μl; Invitrogen); 48 h after transfection, the cells were harvested and the luciferase activities of the lysates were determined using a dual luciferase assay reporter system (Promega, Fitchburg, WI, USA), according to the manufacturer's instructions.
Senescence assay
Senescence assays were performed according to the manufacturer's protocol for the SA-β-Gal staining kit (Cell Signaling Technology). At 48 h after transfection of miR-506 or miR-ctrl, the cells were rinsed with PBS, fixed for 15 min and stained with β-Gal overnight; a resulting blue colour indicated β-Gal-positive cells. The β-Gal-positive rate was calculated using a microscope at × 200 magnification).
Immunohistochemical staining
Immunohistochemical staining was performed on tumour tissues from the mouse orthotopic model and tissue microarrays that included samples from 92 patients with serous ovarian cancer, both of which were assembled for our previous study [12] . Rabbit anti-human monoclonal antibody against Ki-67 (1:1500, ab15580; Abcam, Cambridge, MA, USA), rabbit anti-human polyclonal antibody against CDK4 (1:250, c-22; Santa Cruz Biotechnology), rabbit anti-human polyclonal antibody against CDK6 (1:100, ab-13; Sigma), rabbit anti-human polyclonal antibody against FOXM1 (1:400, c-20; Santa Cruz Biotechnology) and EnVision + System-HRP rabbit (Dako, Carpentaria, CA, USA) were used. Ki-67-, CDK4-and CDK6-positive cells were defined as those with brown staining in the nucleus, and the expression of these proteins was evaluated using the percentage of positive tumour cells in 1000 tumour cells. FOXM1-positive cells were defined as those with immunoreactivity in both cytoplasm and nucleus and were quantified using a scoring system of 0-9, multiplied by the intensity of the signal, and classified by the percentage of positive cells (0, no signal, 0%; 1, weak signal, < 25%; 2, intermediate signal, 25-50%; and 3, strong signal, >50%). miRNA in situ hybridization and RT-PCR had been performed in our previous study, and low and high miR-506 expressions were defined as scores of <6 and ≥ 6, respectively [12] . ′ -UTR-luciferase reporter, wild-type (wt) or mutant (mt) and miR-ctrl or miR-506 mimic for 48 h before analysis. Firefly luciferase activity of the reporter was normalized to the internal Renilla luciferase activity. Mean ± SD of three independent experiments are shown; *p < 0.05. (D, E) Western blot analysis showed that miR-506 down-regulated the levels of CDK4 and CDK6 proteins in three ovarian cancer cell lines, while anti-miR-506 up-regulated CDK4/6. (F) MiR-506 binding sites were predicted in the 3 ′ -UTRs of CDK4 and CDK6 by TargetScan.
Results
MiR-506 directly targeted CDK4 and CDK6 expression through their 3 ′ -untranslated regions
To identify genes potentially regulated by miR-506, microarray analysis was performed on HeyA8 ovarian cancer cells transfected with either miR-506 mimic (miR-506) or a scrambled negative miRNA control (miR-ctrl). Analysis revealed that CDK4 and CDK6 mRNA were decreased by miR-506 over-expression ( Figure 1A ). This result was confirmed with western blotting, which showed that miR-506 over-expression decreased CDK4 and CDK6 protein levels ( Figure 1D ). Conversely, HeyA8, SKOV3 and OVCA433 ovarian cancer cells transfected with miR-506 antisense oligonucleotides (anti-miR-506 LNA) had higher levels of CDK4 and CDK6 proteins than cells transfected with anti-miR-ctrl ( Figure 1E ).
The miRNA target prediction algorithm TargetScan 6.0 predicted that the 3 ′ -UTRs of CDK4 and CDK6 mRNA contain putative miR-506 binding sites (Figure 1 F) . The potential binding site and the flanking sequences of CDK4 are highly conserved across mammals (see supplementary material, Figure  S1 ). To determine whether miR-506 regulates CDK4 and CDK6 through binding to their 3 ′ -UTRs, we cloned the CDK4 and CDK6 3 ′ -UTRs into the pmirGLO luciferase reporter vector and transfected one of these pmirGLO vectors or the parent luciferase expression vector, with miR-506 mimic or miR-ctrl, into HeLa cells. Co-transfection of pmirGLO-CDK4-3 ′ -UTR or -CDK6-3 ′ -UTR-F1 and miR-506 mimic resulted in lower luciferase activity than in cells co-transfected with miR-ctrl ( Figure 1B, C) , suggesting that miR-506 targets these two genes directly.
To confirm that miR-506 specifically regulates these two genes, we generated the con 
-CDK6 -3
′ -UTR-mutant, in which the miR-506 binding site sequence on the 3 ′ -UTR was deleted. These constructs were then co-transfected with miR-506 mimic or miR-ctrl into HeLa cells. Deletion of the miR-506 binding site from the 3 ′ -UTRs of these two genes (CDK4 and CDK6-F1) abolished the effects of miR-506 on luciferase activity. Taken together, these results provide evidence that miR-506 specifically targets the 3 ′ -UTR regions of CDK4 and CDK6 and thus inhibits the expression of these genes.
MiR-506 inhibited viability of ovarian cancer cells
To explore the effect of miR-506 on cell viability, an MTT cell assay was used. HeyA8 and SKOV3 cells were transiently transfected with miR-506 mimic, miR-ctrl/anti-miR506 or anti-miR-ctrl. At 96 h after transfection, as shown in Figure 2A , miR-506 had inhibited HeyA8 cell viability by 35% (p < 0.01) and SKOV3 viability by 40% (p < 0.01) compared to miR-ctrl, whereas anti-miR506 had increased HeyA8 cell viability by 155% (p < 0.01) and SKOV3 viability by 81% (p < 0.01) compared to anti-miR-ctrl (see supplementary material, Figure S2 ).
The effect of miR-506 on proliferation was further evaluated by BrdU proliferation assay. As shown in Figure 2B , miR-506 mimic significantly decreased the BrdU-positive rate in both HeyA8 and SKOV3 cells. Consistently with that finding, anti-miR506 LNA increased the BrdU-positive rate (see supplementary material, Figure S3 ). Furthermore, miR-506 dramatically impaired the colony-forming capacity of ovarian cancer cells ( Figure 2C ). The colony-formation capacity of miR-506-transfected cells was much lower than that of cells transfected with miR-ctrl in several cell lines, and cells transfected with anti-miR-506 displayed greater colony-formation capacity than cells transfected with anti-miR-ctrl.
Because CDK4 and CDK6 play important roles in G 0/1 -S phase transition by associating with the D-type cyclins, we examined the cell cycle distribution of cells over-expressing miR-506. Both HeyA8 and SKOV3 cells transfected with miR-506 displayed a greater percentage of cells in G 0/1 phase and fewer cells in S phase than their counterparts transfected with miR-ctrl ( Figure 3A) . The same phenomenon was observed in other ovarian cancer cells (see supplementary material, Figure S4 ). Conversely, anti-miR506 transfection led to mild decreases (not significant) in the percentage of G 0/1 phase cells. These results suggest that the growth-suppressive effect of miR-506 is at least partly due to a G 0/1 phase arrest.
To examine whether the growth-inhibitory effect of miR-506 involved apoptosis, we performed Apo-BrdU and annexinV apoptosis assays after transfection of miR-506 or miR-ctrl. HeyA8 cells displayed a mild but non-significant increase in apoptosis rates 48 h after transfection of miR-506 compared to miR-ctrl (p > 0.05; Figure 3B , C). These results suggest that apoptosis was not a key factor in the miR-506-mediated decrease in ovarian cancer cell growth. 
MiR-506 inhibited CDK4/6-FOXM1 signalling and promoted senescence
The effects of miR-506 on levels of cyclinD1, cyclinD3 and forkhead box M1 (FOXM1), key CDK4/6 substrates, were then examined. Both HeyA8 and SKOV3 cells transfected with miR-506 had lower FOXM1 protein levels, but no significantly different cyclinD1 or cyclinD3 levels, than cells transfected with miR-ctrl ( Figure 3D ). Because recent studies showed that CDK4/6-FOXM1 signalling mediated suppression of senescence, the activity of Senescence-associated β-galactosidase (SA-β-Gal), a marker of senescence, was examined in cells transfected with miR-506. As expected, both HeyA8 and SKOV3 cells transfected with miR-506 displayed a significantly greater percentage of SA-β-Gal-positive cells than controls (7.79-54.84% and 1.06-27.37%, respectively, p < 0.01; Figure 3E ).
CDK4/6 contributed to the growth suppression and cell senescence induced by miR-506
To elucidate whether the growth-suppressive and senescence-inducing effects of miR-506 were mediated by repression of CDK4 and CDK6 in ovarian cancer cells, gain-of-function and loss-of-function studies were performed. First, CDK4 or CDK6 were silenced to investigate whether reduced expression of CDK4 or CDK6 could mimic the suppressive effect of miR-506. HeyA8 cells were transfected with siRNA for CDK4 and CDK6, singly or in combination. As shown in Figure 4 , knockdown of CDK4, CDK6 or both led to significant cell growth inhibition, similar to that induced by miR-506. Knockdown of CDK6 or both CDK4 and CDK6 also led to cell cycle arrest and increased senescence, like those observed with miR-506 over-expression. The levels of FOXM1 were also examined in these cells, and the results showed that knockdown of both CDK4 and CDK6 were required for down-regulation of FOXM1.
We then studied whether ectopic expression of CDK4 or CDK6 could rescue the suppressive effects of miR-506. HeyA8 cells were transfected with CDK4 or CDK6 for 48 h and then with miR-506 or miR-ctrl altered to encode the full-length sequence without the 3 ′ -UTR region. Over-expression of CDK4 or CDK6 could partially rescue the down-regulation of FOXM1 ( Figure 4E ). Our results showed that ectopic expression of CDK4 or CDK6 could partially rescue miR-506-induced cell growth suppression and senescence (Figure 4 F, H) .
Systemically delivered miR-506 inhibited CDK4 and CDK6 expression and reduced proliferation in vivo
In our previous study, miR-506-transfected SKOV3 cells showed epithelial cell features, including increased E-cadherin expression. Delivery of miR-506 incorporated in DOPC nanoliposomes (miR-506-DOPC) resulted in significant reductions in numbers of tumour nodules and tumour weights in orthotopic mouse models of SKOV3-IP1 and HeyA8-IP1 ovarian tumours; immunohistochemical analysis of the tumours showed significant suppression of SNAI2 and vimentin and induction of E-cadherin [12] . For the studies reported here, immunohistochemical staining for CDK4, CDK6 and Ki-67 was performed on the tumour tissues collected from these mice. Concordant with our in vitro findings, miR-506 treatment led to significantly decreased CDK4 and CDK6 expression (p < 0.05 and p < 0.05, respectively). Moreover, the number of Ki-67-positive cells was also significantly lower in both SKOV3 and HeyA8 than among controls (p < 0.01 and p < 0.05, respectively, Figure 5 ).
High miR-506 expression was associated with decreased CDK4/CDK6-FOXM1 signalling and lower proliferation in human serous ovarian carcinoma To investigate the modulation by miR-506 of the key CDK4/CDK6-FOXM1 signalling proteins in human ovarian cancer tissue, microarrays of tissues from 92 patients with ovarian cancer that we developed for a previous study were subjected to immunohistochemical staining for CDK4, CDK6, FOXM1 and Ki-67 and their correlations with miR-506 expression were analysed (determined by RT-PCR and miRNA in situ hybridization) [12] . As shown in Figure 6 , miR-506 expression was inversely correlated with CDK4, CDK6 and FOXM1 protein expression in the 92 cases of serous ovarian cancer (p < 0.05 for all), which was consistent with our in vitro and animal model results. Furthermore, high miR-506 expression was significantly associated with low Ki-67 expression (p < 0.05). Altogether, our results from in vitro, in vivo and human tumour samples demonstrate that miR-506 inhibited the CDK4/CDK6-FOXM1 signalling pathway and consequently decreased cell proliferation in ovarian cancer.
Discussion
We recently reported that miR-506 functions as a tumour suppressor in serous ovarian cancer. Decrease of miR-506 expression by methylation was observed in patients with serous ovarian cancer who had shorter survival, an observation that has been validated in multiple datasets (Bentink dataset and Bagnoli dataset) [12] . Nanoparticle delivery of miR-506 significantly blocked tumour nodule development and growth in an orthotopic mouse model [12, 14] , and the anti-tumour effect of miR-506 was partially attributed to its capacity to inhibit the EMT. In this study, we demonstrate that miR-506 plays a substantial role as a tumour suppressor in ovarian cancer, and that this miRNA has multiple functions, including inhibiting proliferation and promoting senescence, in addition to inhibiting the EMT (Figure 7 ). During cancer promotion and progression, abrogation of senescence is accompanied by the EMT, illustrating that these two biological processes cross paths in cancer development [15, 16] .
Our mechanistic investigations revealed that miR-506 regulates cell proliferation and senescence by directly targeting its binding sites on the 3 ′ -UTRs of CDK4 and CDK6. CDK4/6 plays an important role in G 0/1 -S phase transition by associating with the D-type cyclins and phosphorylating the retinoblastoma protein (Rb) [17]. Deregulation of the CDK4/6-cyclin D signalling pathway is among the most common aberrations found in human cancer, including ovarian cancer [18] [19] [20] . Alteration of the p16-cyclinD1-CDK4-pRb pathway (ie the Rb pathway) has been reported to be a significant and independent indicator of poor overall survival in ovarian cancer [21] . CDK4/6 has been considered a desirable target for cancer therapies [22] . The CDK4/6 inhibitor PD-0332991 is currently undergoing clinical testing in several cancer types [23] [24] [25] .
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CDK4/6 has been reported to stabilize and activate the transcription factor FOXM1, whose network is activated in 84% of serous ovarian cancer cases (TCGA data) [13] . CDK4/6-FOXM1 signalling may suppress levels of reactive oxygen species and protect cancer cells from senescence [26, 27] . Senescence is a tumour-suppressive mechanism and must be overcome during immortalization and transformation [28, 29] . Our results demonstrate that miR-506 caused little to no increase in ovarian cancer cell apoptosis. However, miR-506 induced a dramatic increase in cellular senescence, and FOXM1 protein levels were decreased following miR-506 over-expression.
Emerging evidence from in vitro and in vivo studies has implicated the oncogenic transcription factor FOXM1 in cell migration, invasion, angiogenesis and metastasis [30] [31] [32] , which affirms its significance for therapeutic intervention [33] . FOXM1 has been shown to be an important regulator of EMT. Specifically, FOXM1 promoted EMT in breast cancer cells by stimulating SNAI2 [34] . FOXM1 was involved in EMT induced by TGFβ1 [35, 36] . H292-FoxM1 cells expressed lower levels of E-cadherin and higher levels of vimentin and N-cadherin [37] . This finding that miR-506 can repress CDK4/6-FOXM1 signalling provides a rationale for treatment of ovarian cancer with miR-506.
Taken together, our findings shed light, for the first time, on the mechanism of miR-506 as a tumour-suppressive miRNA in human ovarian cancer, revealing that this suppression is mediated, at least partly, through repression of CDK4/6-FOXM1 signalling. Our data provide evidence that reintroduction of miR-506 into tumour cells may be an effective therapeutic strategy, reducing the expression of oncogenic target genes. Although miRNA-based therapeutics are still in their infancy [14] , our findings on miR-506 are encouraging and suggest that this miRNA is a potential target for the treatment of ovarian cancer. This finding is consistent with those reported in malignant transformed human bronchial epithelial cells [9] . In another study, however, the miR-506-514 cluster was shown to promote cell growth in melanoma [10] . These controversial results suggest that the role of miR-506 may be tumour-specific and highly dependent on its targets in different cancer cells. Nevertheless, miR-506 emerges as a strong ovarian cancer-suppressing agent that blocks two clinically important cancer hallmarks, EMT and cell proliferation, while enhancing cell senescence.
